Coronavirus Vaccine Problems Media ArticlesExcerpts of Key Coronavirus Vaccine Problems Media Articles in Major Media
Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.
The Trump administration has compared Operation Warp Speed's crash program to develop a COVID-19 vaccine to the Manhattan Project. And like the notoriously secretive government project to make the first atomic bomb, the details of Operation Warp Speed's work may take a long time to unravel. One reason is that Operation Warp Speed is issuing billions of dollars' worth of coronavirus vaccine contracts to companies through a nongovernment intermediary, bypassing the regulatory oversight and transparency of traditional federal contracting mechanisms, NPR has learned. Instead of entering into contracts directly with vaccine makers, more than $6 billion in Operation Warp Speed funding has been routed through a defense contract management firm called Advanced Technologies International, Inc. ATI then awarded contracts to companies working on COVID-19 vaccines. As a result, the contracts between the pharmaceutical companies and ATI may not be available through public records requests, and additional documents are exempt from public disclosure for five years. [Robin] Feldman, of UC Hastings, says the administration's comparison of Operation Warp Speed to the Manhattan Project is troubling. "I think that's completely the wrong image," she says. "The right analogy, I think, for Operation Warp Speed is the penicillin effort in World War II. We can do a lot of good together, but we have to make sure pharma companies aren't taking advantage of the crisis."
Note: Read an excellent article showing how most of these contracts are linked to the CIA and DHS and more. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and the coronavirus from reliable major media sources.
The Centers for Disease Control and Prevention was created to stop deadly pathogens. But 2020 has been a disaster for the CDC. The agency's response to the worst public health crisis in a century - the coronavirus pandemic - has been marked by technical blunders and botched messaging. The agency has endured false accusations and interference by Trump administration political appointees. Worst of all, the CDC has experienced a loss of institutional credibility at a time when the nation desperately needs to know whom to trust. The stumbles started early in the pandemic, with the botched rollout of test kits suspected of being contaminated at a CDC lab in late January. But the agency's most chronic problem has been the inability to speak directly and persuasively to the American public. That's because it has been muzzled ... by political operatives. White House officials have pressured the CDC to change guidance over the last several months to align the guidelines more closely with the administration's message that the pandemic is under control, federal health officials have said. Those actions include revised CDC guidance on mask-wearing and the reopening of religious institutions and schools. "Every big public health response has two components: the public health emergency and the political emergency," said a CDC epidemiologist who spoke on the condition of anonymity out of fear of retaliation. "I never would have expected the level of political interference we're seeing now. It's so sad."
[During] the "swine flu affair of 1976" ... a US president decided to rush a vaccine to the entire American population based on ill-founded science and political imprudence. The mistakes that followed hold lessons for today. Lawsuits, side-effects and negative media coverage followed, and the events dented confidence in public health for years to come. It began at a US Army training base. In February 1976, several soldiers at Fort Dix fell ill with a previously unrecognised swine flu. In March, President Ford announced a $137m (Ĺ67.5m in 1976) effort to produce a vaccine by the autumn. Its goal was to immunise every man, woman and child in the US. The president himself was vaccinated on television on 14 October, further heightening perceptions that this was a politicised event. As has happened throughout the Covid-19 pandemic of 2020, the scientists could only give the best advice they could based on incomplete knowledge. As the months continued – still with no outbreak – new problems arose. Millions of vaccinations meant dozens of cases of Guillain-Barre syndrome, a rare problem where the body's immune system attacks the nerves. The swine flu strain spotted at Fort Dix was not dangerous, and there would be no pandemic. When politicians in the present day talk of "the science" as if it is a complete body of knowledge, a manual for what to do, it neglects the uncertainty of evidence and ignores that science is a human endeavour. The swine flu affair, the New York Times concluded, had been a "sorry debacle" and "fiasco" marked by political expediency and unwarranted confidence.
Note: Watch an incrediby revealing "60 Minutes" video clip on this tragic story of greed and corruption at the highest levels. Read also a Los Angeles Times article on this 1976 "debacle" where only one died from the flu while at least 25 died from the vaccine. For more along these lines, see concise summaries of deeply revealing news articles on government corruption and vaccines from reliable major media sources.
Moderna, Pfizer, AstraZeneca, and Johnson & Johnson are leading candidates for the completion of a Covid-19 vaccine likely to be released in the coming months. These companies have published their vaccine trial protocols. Close inspection of the protocols raises surprising concerns. These trials seem designed to prove their vaccines work, even if the measured effects are minimal. Prevention of infection is not a criterion for success for any of these vaccines. In fact, their endpoints all require confirmed infections and all those they will include in the analysis for success, the only difference being the severity of symptoms between the vaccinated and unvaccinated. Measuring differences amongst only those infected by SARS-CoV-2 underscores the implicit conclusion that the vaccines are not expected to prevent infection, only modify symptoms of those infected. We all expect an effective vaccine to prevent serious illness if infected. Three of the vaccine protocols - Moderna, Pfizer, and AstraZeneca - do not require that their vaccine prevent serious disease only that they prevent moderate symptoms which may be as mild as cough, or headache. A vaccine must significantly or entirely reduce deaths from Covid-19. None list mortality as a critical endpoint.
Note: Read also this article in BMJ (British Medical Journal) titled "Will covid-19 vaccines save lives? Current trials aren't designed to tell us." And this CNBC article is titled "Dr. Fauci says masks, social distancing will still be needed after a Covid-19 vaccine." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccine issues from reliable major media sources.
If you were to approve a coronavirus vaccine, would you approve one that you only knew protected people only from the most mild form of Covid-19, or one that would prevent its serious complications? The answer is obvious. You would want to protect against the worst cases. But that's not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca ... are approaching the problem. According to the protocols for their studies ... a vaccine could meet the companies' benchmark for success if it lowered the risk of mild Covid-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death. To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That's not what these trials will determine. Influenza vaccines ... reduce the risk of mild disease in healthy adults. But there is no solid evidence they reduce the number of deaths. In fact, significant increases in vaccination rates over the past decades have not been associated with reductions in deaths. Moderna and Pfizer acknowledge their vaccines appear to induce side effects that are similar to the symptoms of mild Covid-19. In Pfizer's early phase trial, more than half of the vaccinated participants experienced headache, muscle pain and chills. If the vaccines ultimately provide no benefit beyond a reduced risk of mild Covid-19, they could end up causing more discomfort than they prevent.
Note: Did you know that the FDA allows cancer cells to be used in vaccines? And the Vatican has stated "It is morally acceptable to receive Covid-19 vaccines that have used cell lines from aborted fetuses." For more along these lines, see concise summaries of deeply revealing news articles on coronavirus vaccines from reliable major media sources. Then explore the excellent, reliable resources provided in our Coronavirus Information Center.
AstraZeneca revealed details of its large coronavirus vaccine trials on Saturday, the third in a wave of rare disclosures by drug companies under pressure to be more transparent about how they are testing products that are the world's best hope for ending the pandemic. Polls are finding Americans increasingly wary of accepting a coronavirus vaccine. Experts have been particularly concerned about AstraZeneca's vaccine trials, which began in April in Britain, because of the company's refusal to provide details about serious neurological illnesses in two participants, both women, who received its experimental vaccine in Britain. Those cases spurred the company to halt its trials twice, the second time earlier this month. The studies have resumed in Britain, Brazil, India and South Africa, but are still on pause in the U.S. About 18,000 people worldwide have received AstraZeneca's vaccine so far. The company has released few details about the two cases of serious illness in its trial. The first participant received one dose of the vaccine before developing inflammation of the spinal cord, known as transverse myelitis. The condition can cause weakness in the arms and legs, paralysis, pain and bowel and bladder problems. The company said it had not confirmed a diagnosis in the second case, a participant who got sick after the second dose of the vaccine. A person familiar with the situation who spoke with The Times on the condition of anonymity said the participant's illness had been pinpointed as transverse myelitis.
Note: Why won't the company let the two who became seriously ill speak to the media? And why initially did they hide the fact that the illnesses were serious? And why are top vaccine executives now dumping their shares of stocks? For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.
Whether the coronavirus vaccine developed by Moderna succeeds or not, executives at the small biotech company have already made tens of millions of dollars by cashing in their stock. An NPR examination of official company disclosures has revealed additional irregularities and potential warning signs. Since January, CEO StĂ©phane Bancel has sold roughly $40 million worth of Moderna stock; Chief Medical Officer Tal Zaks has sold around $60 million; and President Stephen Hoge has sold more than $10 million. The stock sales first came to widespread notice after Moderna announced positive early data from a vaccine trial in May. At that point, the company's share price jumped and official disclosures showed executives cashing in their shares for millions of dollars. Advocates have questioned whether it's appropriate for executives to privately profit before bringing the vaccine to market, especially when American taxpayers have committed roughly $2.5 billion to the company's vaccine development. Moderna says its executives pre-scheduled their stock sales long in advance. Those schedules - known as 10b5-1 plans - can act as a defense to charges of insider trading. But the plans have to be put in place when executives do not have confidential inside information. NPR has found multiple executives adopted or modified their plans just before key announcements about the company's vaccine. That has raised questions about whether they were aware of nonpublic information when they planned their stock trades.
Note: Explore a revealing NBC article titled "Secret, powerful panels will pick Covid-19 vaccine winners." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and Big Pharma corruption from reliable major media sources.
A four-inch wafer of silicon has been turned into an army of one million microscopic, walking robots, thanks to some clever engineering employed by researchers at Cornell University in New York. In a paper, published Wednesday in the journal Nature, a team of roboticists detail the creation of their invisible army of robots, which are less than 0.1mm in size (about the width of a human hair) and cannot be seen with the naked eye. The robots ... take advantage of an innovative, new class of actuators, which are the legs of the microrobots. Controlling movement in these tiny machines requires the researchers to shine a laser on minuscule light-sensitive circuits on their backs, which propels their four legs forward. They've been designed to operate in all manner of environments such as extreme acidity and temperatures. One of their chief purposes, the researchers say, could be to investigate the human body from the inside. The team was able to build incredibly small legs, which are connected to two different patches on the back of the robot - one for the front pair of legs, one for the back. Alternating light between the patches propels the microrobot forward. The research team were able to show the microrobots devices could fit within the narrowest hypodermic needle and thus, could be "injected" into the body. The machines aren't intelligent enough to target a diseased cell or respond to stimuli, so there's no application for this invisible army. However, the researchers said that "their capabilities can rapidly evolve."
Note: Remember that secret military projects are often 20 years or more advanced of anything made public. Could this technology have already been developed in secret projects and used in military vaccines? Yale professor Charles Morgan describes in this two-minute video (or this one) how cells injected through hypodermic needles can cause foreign substances to be manufactured in our bodies, how they can alter a person's memory, and much more. His full presentation on psycho-neurobiology and war given at West Point Military Academy is quite disturbing.
What Americans need to understand about the race to find vaccines and treatments for Covid-19 is that in the U.S., even when companies appear to downshift from maximum greed levels – and it's not at all clear they've done this with coronavirus treatments – the production of pharmaceutical drugs is still a nearly riskless, subsidy-laden scam. Americans reacted in horror five years ago when a self-satisfied shark of an executive named Martin Shkreli, a.k.a. the "Pharma Bro," helped his company, Turing Pharmaceuticals, raise the price of lifesaving toxoplasmosis drug Daraprim from $13.50 to $750 per pill. Shkreli, who smirked throughout congressional testimony ... was held up as a uniquely smug exemplar of corporate evil. Really, the whole industry is one big Shkreli, and Covid-19 – a highly contagious virus with unique properties that may require generations of vaccinations and booster shots – looms now as the ultimate cash cow for lesser-known Pharma Bros. "The power of the industry combined with fear is driving extraordinary spending," says U.S. Rep. Lloyd Doggett (D-Texas), who has been ... warning about pandemic profiteering. "It all suggests rosy times ahead for the pharmaceutical industry." Recent House and Senate emergency-spending bills allocate as much as $20 billion or more for vaccine development, and another $6 billion for manufacturing and distribution. "The public will pay for much research and manufacturing," says Doggett. "Only the profits will be privatized."
Across the pharmaceutical and medical industries, senior executives and board members are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March, according to figures compiled for The New York Times. The sudden windfalls highlight the powerful financial incentives for company officials to generate positive headlines in the race for coronavirus vaccines and treatments, even if the drugs might never pan out. Some officials at the Department of Health and Human Services have grown concerned about whether companies are trying to inflate their stock prices by exaggerating their roles in Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. In some cases, company insiders ... appear to be pouncing on opportunities to cash out while their stock prices are sky high. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. "It is inappropriate for drug company executives to cash in on a crisis," said Ben Wakana, executive director of Patients for Affordable Drugs. "Every day, Americans wake up and make sacrifices during this pandemic. Drug companies see this as a payday."
On June 26, a small South San Francisco company called Vaxart made a surprise announcement: A coronavirus vaccine it was working on had been selected by the U.S. government to be part of Operation Warp Speed, the flagship federal initiative to quickly develop drugs to combat Covid-19. The race is on to develop a coronavirus vaccine, and some companies and investors are betting that the winners stand to earn vast profits from selling hundreds of millions – or even billions – of doses to a desperate public. Across the pharmaceutical and medical industries, senior executives and board members ... are making millions of dollars after announcing positive developments, including support from the government, in their efforts to fight Covid-19. After such announcements, insiders from at least 11 companies – most of them smaller firms whose fortunes often hinge on the success or failure of a single drug – have sold shares worth well over $1 billion since March. Senior officials appear to be pouncing on opportunities to cash out. And some companies have awarded stock options to executives shortly before market-moving announcements about their vaccine progress. Some companies are attracting government scrutiny for ... using their associations with Operation Warp Speed as marketing ploys. Vaxart's news release declared: "Vaxart's Covid-19 Vaccine Selected for the U.S. Government's Operation Warp Speed." But Vaxart is not among the companies selected to receive significant financial support from Warp Speed.
Note: MSN strangely removed this article a few days after posting it. A similar article by the New York Times titled "The race for a coronavirus vaccine is making some corporate insiders very rich" is available here. For more along these lines, see concise summaries of deeply revealing news articles on big Pharma corruption and the coronavirus from reliable major media sources.
Moderna CEO StÄ‚©phane Bancel more than tripled the number of his company shares to be sold through an executive stock plan that was changed just days after the biotech in May announced positive early results for its coronavirus vaccine. Moderna's shares spiked on the May news, rising 30% in just one day. After seeking the executive stock plan change in May, Bancel sold more than 72,000 Moderna shares in the first 16 days of July, generating nearly $4.8 million for the executive. That was more than triple the 22,000 shares he had previously scheduled to sell during the same period through the company's executive trading plan. Another top Moderna executive, President Stephen Hoge, also had his pre-programmed executive trading plan reset around the same time. The change allowed him to sell $1.9 million worth of Moderna stock in the first two weeks of July. The executives' ... sales were made through what are known as 10b5-1 stock plans. These arrangements must be set up or amended at least 30 days before any transactions are executed; they are commonly used at publicly traded companies to help shield executives from potential claims of insider trading. The fact that the plans were changed during the pandemic as news was emerging about the company's closely watched coronavirus vaccine raises new questions about how Moderna executives have pocketed millions of dollars in recent months.
The Trump administration this month announced that one of its largest pandemic-related contracts would go to a little-known biodefense company named Emergent BioSolutions. The $628 million deal to help manufacture an eventual vaccine cemented Emergent's status as the highest-paid and most important contractor to the HHS office responsible for preparing for public health threats and maintaining the government's stockpile of emergency medical supplies. Emergent has long been the government's sole provider of BioThrax, a vaccine for anthrax poisoning. Emergent's advocacy for biodefense spending over more than a decade was aided by influential allies in Washington and tens of millions of dollars in lobbying campaigns. "It has strategically placed itself to be, let's just say, the company that can't fail," said a former senior government official who worked with Emergent on stockpile operations. The company that would become Emergent began as BioPort Corp., formed in 1998 to buy an aging, state-owned company in Lansing, Mich., that was the only licensed supplier of anthrax vaccine to the Pentagon. The Pentagon ... awarded a $29 million no-bid contract for the anthrax vaccine, BioThrax. Controversy swamped the operation. Hundreds of U.S. troops who received the BioThrax treatment complained of bad reactions, such as headaches and nerve problems. Some troops risked courts-martial by refusing vaccination. Emergent spent nearly $4 million on lobbying last year alone.
Note: To understand the huge influence of lobbying and profits on the development and stockpiling of vaccines, don't miss reading this entire, eye-opening article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption and vaccines from reliable major media sources.
Moderna set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the results released on May 18, a series of transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna (MRNA) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value despite the fact it has no marketed products. By the time the selling was disclosed to the public via securities filings, Moderna's stock price had crashed back to Earth. The timing of the transactions - coupled with concerns from some medical experts that Moderna overstated the significance of its Phase 1 vaccine trial - should be investigated by authorities. Thomas Gorman, [a] former SEC official, said the agency should "absolutely" be investigating the situation at Moderna.
Note: Why didn't the media report that the Moderna vaccine trial had a 20% serious injury rate in the high dose group? Learn about this and much more in this revealing article. For more along these lines, see concise summaries of deeply revealing news articles on Big Pharma corruption from reliable major media sources.
The chief scientist brought on to lead the Trump administration's vaccine efforts has spent the last several days trying to disentangle pieces of his stock portfolio and his intricate ties to big pharmaceutical interests. The scientist, Moncef Slaoui, is a venture capitalist and a former longtime executive at GlaxoSmithKline. Most recently, he sat on the board of Moderna, a Cambridge, Mass., biotechnology firm with a $30 billion valuation that is pursuing a coronavirus vaccine. He resigned when President Trump named him last Thursday to the new post as chief adviser for Operation Warp Speed, the federal drive for coronavirus vaccines and treatments. Just days into his job, the extent of Dr. Slaoui's financial interests in drug companies has begun to emerge: The value of his stock holdings in Moderna jumped nearly $2.4 million, to $12.4 million when the company released preliminary, partial data from an early phase of its candidate vaccine trial. Dr. Slaoui did not come on board as a government employee. Instead, he is on a contract ... that leaves him exempt from federal disclosure rules that would require him to list his outside positions, stock holdings and other potential conflicts. And the contract position is not subject to the same conflict-of-interest laws and regulations that executive branch employees must follow. Dr. Slaoui ... is not the first Trump administration official with close relationships to drug and health care companies. Alex M. Azar II, the health and human services secretary, is a former Eli Lilly executive.
Note: If the above link fails, this article is also available here. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in Big Pharma from reliable major media sources.
When pharmaceutical company Moderna issued a press release about the promising results of its Phase I clinical trial for a coronavirus vaccine, the media and the markets went wild. Upon examining Moderna's non-peer reviewed press release, the actual data on the vaccine's success is ... flimsy. Of the 45 patients who received the vaccine, the data on "neutralising antibody data are available only for the first four participants in each of the 25-microgram and 100-microgram dose level cohorts." In other words, that means that when it comes to finding out whether the vaccine elicits an antibody response that could potentially fight the coronavirus, they only had data on eight patients. That's not enough to do any type of statistical analysis and it also brings into question the status of the other 37 patients who also received the vaccine. Moderna's messenger RNA vaccine ... uses a sequence of genetic RNA material produced in a lab that, when injected into your body, must invade your cells and hijack your cells' protein-making machinery called ribosomes to produce the viral components that subsequently train your immune system to fight the virus. There are unique and unknown risks to messenger RNA vaccines, including the possibility that they generate strong type I interferon responses that could lead to inflammation and autoimmune conditions. Messenger RNA vaccines have never before been brought to market for human patients.
Note: To learn about the serious risks and dangers of these mRNA vaccines, don't miss the vitally important information given by Christiane Northrup, MD, in the first five minutes of this highly revealing video. Reader's Digest named Dr. Northrup one of "The 100 Most Trusted People in America." Dr. Northrup's work has been featured on The Oprah Winfrey Show, the Today Show, NBC Nightly News, Good Morning America, 20/20, and The Dr. Oz Show. For more, see concise summaries of revealing news articles on the coronavirus and vaccines from major media sources.
The claim: Florida Gov. Ron DeSantis's executive order allows civilians to receive a coronavirus vaccination and 'it might be happening.' An Instagram post from April claims an executive order signed by Florida Gov. Ron DeSantis allows the state to require its "civilians" to receive a coronavirus vaccination. The Instagram post [refers] to an executive order issued by DeSantis on March 23. It mandates travelers arriving in Florida self-quarantine for "14 days from the time of entry into the state of Florida or the duration of the person's presence in the state of Florida, whichever is shorter." Section B of the executive order ... references powers given under section 5 of Florida statute 381.00315, which details the proceedings of public officials in the time of a public health emergency. The statute says the government, amid a public health emergency when imposing isolation or quarantine, can adopt rules such as "tests or treatment, including vaccination, for communicable disease required before employment or admission to the premises or to comply with an isolation or a quarantine." It is true that Florida statute 381.00315, as cited in DeSantis's executive orders, makes it legal to order an individual to be vaccinated, among other public safety measures, during a public health emergency. But because there is not yet a coronavirus vaccine, it is false to imply this action is imminent.
Note: The Instagram post did not say that the vaccine mandate is imminent. Notice how far the media will stretch to discredit valid information. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus from reliable major media sources.
One by one, vaccine developers at a White House roundtable convened by President Donald Trump in early March pitched their product as a viable solution to the coronavirus. StĂ©phane Bancel of Moderna Inc. glanced across the table at the nation's top infectious disease expert, Dr. Anthony Fauci, and said he is "very proud to be working with the US government and to have already sent, in only 42 days from the sequence of the virus, our vaccine to Dr. Fauci's team at the NIH." Bancel went on to say that he needed just "a few months" to start phase two of a three-part clinical trial of the sort that typifies vaccine development. (The entire process often takes more than a decade.) The day after the roundtable, the FDA green-lit Moderna's product for trial, making it the first vaccine candidate to advance to the first phase of a clinical study, in which an as-yet unapproved vaccine is injected into the arms of a small group of 45 human volunteers. The effort received another boost on April 16, when the federal Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna up to $483 million to accelerate the development and manufacturing of the vaccine. The FDA allowed Moderna's RNA vaccine ... to essentially gloss over the animal-testing that typically precede clinical trials in humans. [Moderna's former director of chemistry Dr. Suhaib] Siddiqi said this is cause for alarm. "I would not let that [vaccine] be injected in my body," he said. "I would demand: Where is the toxicity data from the lab?"
Note: Read a New York Times/MSN article titled "Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine." For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus and vaccines from reliable major media sources.
It might not be until fall 2021 that Americans "can be completely safe" from COVID-19, Bill Gates said in a Tuesday interview with Judy Woodruff on PBS Newshour. That's because it will take more than a year before a vaccine can be developed and deployed, according to researchers working to develop a treatment for COVID-19. "The vaccine is critical, because, until you have that, things aren't really going to be normal," the billionaire philanthropist told Woodruff. "They can open up to some degree, but the risk of a rebound will be there until we have very broad vaccination." Social distancing is helping to lower the number of COVID-19 cases. The goal, Gates explained, is to get that number down to a point where "contact tracing" (a process in which those within close contact with an infected person are closely monitored) can be done, in order to maintain necessary quarantines. To understand what life in the U.S. will look like six to 12 months from now, Gates suggested China as a good model. "They are sending people back to work, but they're wearing masks. They're checking temperatures. They're not doing large sporting events. And so they have been able to avoid a large rebound," he said. Beyond that, "returning to some semblance of normal," as Woodruff put it, can be predicted by watching the behaviors of other countries. Sweden, for example, isn't "locking down quite as much," so their experience will be informative, Gates explained.
Note: In this video interview, Gates says we need to vaccinate everyone in the world. And he wants indemnity in case the vaccine he sponsors ends up killing or injuring many. Learn more about how Gates uses his billions to gain political power. And don't miss this most important video focused on how he is using fear of the virus to promote his agenda to require a "digital certificate" to ensure they've been vaccinated. For more along these lines, see concise summaries of deeply revealing news articles on the coronavirus pandemic from reliable major media sources.
Investment bankers have pressed health care companies on the front lines of fighting the novel coronavirus, including drug firms developing experimental treatments and medical supply firms, to consider ways that they can profit from the crisis. The largest voices in the health care industry stand to gain from billions of dollars in emergency spending on the pandemic, as do the bankers and investors who invest in health care companies. Over the past few weeks, investment bankers have been candid on investor calls and during health care conferences about the opportunity to raise drug prices. Executives joked about using the attention on Covid-19 to dodge public pressure on the opioid crisis. Health and Human Services Secretary Alex Azar previously served as president of the U.S. division of drug giant Eli Lilly and on the board of the Biotechnology Innovation Organization, a drug lobby group. During a congressional hearing ... Azar rejected the notion that any vaccine or treatment for Covid-19 should be set at an affordable price. "We can't control that price because we need the private sector to invest," said Azar. "The priority is to get vaccines and therapeutics. Price controls won't get us there." The initial $8.3 billion coronavirus spending bill passed in early March ... contained a provision that prevents the government from delaying the introduction of any new pharmaceutical to address the crisis over affordability concerns. The legislative text was shaped, according to reports, by industry lobbyists.
Important Note: Explore our full index to key excerpts of revealing major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.